On February 27, 2020 Taiho Pharmaceutical Co. Ltd., ("Taiho") reported its option exercise for AB122 (zimberelimab), an anti-PD-1 monoclonal antibody from Arcus Biosciences, Inc. ("Arcus"), in Japan and certain other territories in Asia (excluding China) (Press release, Taiho, FEB 27, 2020, View Source [SID1234554810]). This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. Taiho has already obtained exclusive rights of AB928 (adenosine receptor antagonist), and therefore this is the second option exercise of the Arcus program.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AB122, an anti-PD-1 monoclonal antibody, has demonstrated clinical activity and safety profile that is consistent with those of currently approved anti-PD-1 therapies. AB122 in combination with AB928 and other standard therapies, is in a broad development program in selected tumor types that include prostate, colorectal, non-small cell lung, pancreatic, triple negative breast and renal cell cancers. As a monotherapy, AB122 is also being evaluated in a tumor-agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options.
In exchange for the option exercise, Taiho has paid an exercise payment in December 2019, and will pay upon achievement, additional clinical, regulatory and commercialization milestones, as well as royalties on net sales for this program.
Through this collaboration, Taiho will further support the development and commercialization of AB122, and will continue its mission to deliver innovative drugs to patients and medical professionals.
About AB122
AB122 is an anti-PD-1 monoclonal antibody currently under development by Arcus. AB122 was originally in-licensed by Arcus from WuXi Biologics in 2017, for worldwide clinical development and commercialization in territories excluding China and Thailand.